Reference : Pharmacological management of type 2 diabetes: what's new in 2017?
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/216142
Pharmacological management of type 2 diabetes: what's new in 2017?
English
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
2017
Expert Review of Clinical Pharmacology
1-12
Yes (verified by ORBi)
International
1751-2433
1751-2441
England
[en] Cardiovascular ; DPP-4 inhibitor ; GLP-1 receptor agonist ; SGLT2 inhibitor ; kidney ; metformin ; new insulin
[en] INTRODUCTION: Novelties in the management of type 2 diabetes are dominated by the commercialisation of new glucose-lowering agents, which offer alternatives to older antidiabetic medications, and by the publication of several prospective placebo-controlled outcome trials, which demonstrated not only cardiovascular safety but also cardiovascular and renal protection with some new medications. Areas covered: Updates regarding the use of glucose-lowering agents are discussed from a clinical point of view. Some new viewpoints concern older antidiabetic agents such as metformin, sulfonylureas and glitazones whose benefit-risk balance has been revisited, especially in high risk patients. The recent data regarding DPP-4 inhibitors (gliptins) focused on the safety profile of this pharmacological class, including in patients with impaired renal function. The highlight concerns the cardiovascular (and renal) protection by some GLP-1 receptor agonists (liraglutide, semaglutide) and SGLT2 inhibitors (empagliflozin, canagliflozin) in patients with high cardiovascular risk. Finally, efficacy and safety of new combinations and advances in insulin therapy will be briefly discussed. Expert commentary: The recent data from randomized controlled trials, meta-analyses and observational real-life studies should trigger a revision of the algorithm for the treatment of hyperglycemia in type 2 diabetes, especially in patients with high cardiovascular and/or renal risk.
http://hdl.handle.net/2268/216142
10.1080/17512433.2017.1376652

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
2017TXT Clean What's new in 2017 T2D management Expert Rev Clin Pharmacol .pdfAuthor preprint433.38 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.